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Pancreatic b cell failure in type 2 diabetes is associ-
ated with functional abnormalities of insulin secre-
tion and deficits of b cell mass. It’s unclear how
one begets the other. We have shown that loss of b
cell mass can be ascribed to impaired FoxO1 func-
tion in different models of diabetes. Here we show
that ablation of the three FoxO genes (1, 3a, and 4)
in mature b cells results in early-onset, maturity-
onset diabetes of the young (MODY)-like diabetes,
with abnormalities of the MODY networks Hnf4a,
Hnf1a, and Pdx1. FoxO-deficient b cells aremetabol-
ically inflexible, i.e., they preferentially utilize lipids
rather than carbohydrates as an energy source.
This results in impaired ATP generation and reduced
Ca2+-dependent insulin secretion. The present find-
ings demonstrate a secretory defect caused by
impaired FoxO activity that antedates dedifferentia-
tion. We propose that defects in both pancreatic b
cell function and mass arise through FoxO-depen-
dent mechanisms during diabetes progression.
INTRODUCTION
Patients with type 2 diabetes display qualitative and quantitative
defects in pancreatic b cell function and mass (Ferrannini,
2010). These deficits are critical components of the transition
fromcompensated insulin resistance (Weyer et al., 1999)—astate
that may affect up to a quarter of the population (Reaven, 1995)—
to overt hyperglycemia, a condition that affects 5%–8% of the
population (National Institute of Diabetes and Digestive and
Kidney Diseases, 2005). Functional defects appear to antedate
quantitative ones at the onset of hyperglycemia (Prentki and
Madiraju, 2012; Rahier et al., 2008), but there is no clear mecha-
nism to explain how b cell dysfunction spawns loss of b cells.CellThe functional impairment of b cells has both genetic (Fajans
and Bell, 2011) and acquired components, with the latter being
partly reversible, at least initially (Savage et al., 1979). Thus, a
challenge for this field of investigation is to identify mechanisms
whereby genetic, environmental, and reversible defects of b cell
function can be subsumed with loss of b cell mass under a gen-
eral theory of b cell failure (Accili et al., 2010).
Transient elevations of glucose or lipids activate transcription
factor FoxO1 through nuclear translocation in b cells (Kawamori
et al., 2006; Kitamura et al., 2005; Martinez et al., 2006), thereby
preventing a chronic dedifferentiation process that appears to be
a shared feature of otherwise different types of murine diabetes
(Talchai et al., 2012b). In addition, we have recently shown that
key tenets of this theory, i.e., dedifferentiation, loss of FOXO1,
and conversion of b cells into a and d cells, also occur in human
type 2 diabetes (Cinti et al., manuscript submitted), providing
further impetus to understand how to forestall or reverse this
process. This model possibly reflects an integrative function of
FoxO1 downstream of heterogeneous signaling pathways, but
doesn’t explain the functional abnormalities that precede b cell
dedifferentiation. b cells express also FoxO3a and FoxO4 (Kita-
mura et al., 2002). The present study fills this gap in knowledge
by demonstrating that, when all three FoxO isoforms are
ablated, b cells develop signal abnormalities of insulin secretion
resulting in MODY-like diabetes, paving the way for eventual
dedifferentiation.
RESULTS
Rationale for the Generation of Triple FoxO Knockout
Mice in b Cells
Genetic ablation of FoxO1 results in b cell dedifferentiation
following repeated pregnancies or in aging animals, as does
the acquired loss of FoxO1 observed in disparate models of
murine diabetes (Talchai et al., 2012b). We first investigated
whether this functional loss of FoxO in diabetic islets extends
to the other two isoforms, FoxO3 and FoxO4. Indeed, in islets
from frankly diabetic mice (random glucose 450 mg/dl), all
FoxOs were decreased (Figures 1A and 1B). Consistent withMetabolism 20, 593–602, October 7, 2014 ª2014 Elsevier Inc. 593
Figure 1. Expression of FoxO in Diabetic
Islets and Generation of Triple FoxO Knock-
outs in b Cells
(A and B) mRNA levels (arbitrary units, AU) and
western blot analysis of the three FoxO isoforms in
islet extracts of 24-week-olddb/db, WT (C57BL/6),
and KO (each islet extract was prepared with
pooled islets from two to three mice per genotype).
(C and D) Representative islet immunohistochem-
istry using antibodies against FoxO1 (C, green),
insulin (Ins, green in D), or glucagon (Gcg, red in D).
Nucleus is stained blue with DAPI.
(E) Ratio of insulin- to glucagon-immunoreactive
areas as determined by immunohistochemistry
(n = 4 mice per genotype, six sections per mouse).
(F) Morphometric analysis of b cell mass in 12-
week-old mice (n = 4 mice per genotype, four
sections per mouse).
(G and H) Quantification of insulin and glucagon
content in acid-ethanol extracts from collagenase-
purified islets (n = 5 mice per group). All data are
presented as means ± SEM. **p < 0.01, ***p <
0.001 by Student’s t test.
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mia, and not insulin resistance (Kitamura et al., 2005), we
found that high-fat feeding of C57BL6 mice was insufficient
to cause this abnormality (Figure S1 available online). In
FoxO1 knockout experiments, we noted a reproducible in-
crease in the expression of FoxO3a and FoxO4 (Talchai
et al., 2012b). We reasoned that this increase might mask
the full phenotype due to FoxO ablation, whereupon we under-
took to ablate the remaining two isoforms in mature b cells,
using Rip-cre mice to delete floxed Foxo1, Foxo3a, and
Foxo4 alleles (Paik et al., 2007). The resulting triple knockout
mice (henceforth, b-FoxO KO) were born at term in predicted
Mendelian ratios and showed no gross or growth abnormality.
Using qPCR, western blotting, and immunohistochemistry,
we determined that expression of the three FoxO proteins
was indeed ablated (Figures 1A–1C). In 12-week-old animals,
islet morphology, relative content of a and b cells, b cell
mass, and pancreatic insulin and glucagon content were
comparable between b-FoxO KO and control littermates (Fig-
ures 1D–1H), as were numbers of endocrine d and Pp-cells
(data not shown). Likewise, there were no discernible differ-594 Cell Metabolism 20, 593–602, October 7, 2014 ª2014 Elsevier Inc.ences between the two genotypes in in-
sulin, glucagon, somatostatin, and Pp
mRNA levels (Figure S1).
Early-Onset, MODY-like Diabetes in
b-FoxO KO Mice
Next, we examined in vivo metabolism.
As early as at 12 weeks of age, b-Foxo
KO mice exhibited hyperglycemia in the
fasted, refed, and random-fed states
when compared to controls that included
mice carrying the Rip-cre transgene, sub-
sumed under the designation ‘‘wild-type’’
(see the Experimental Procedures) (Fig-
ure 2A). This rise was associated withlower plasma insulin levels in fasted, refed, and random-fed an-
imals, although the difference didn’t reach statistical significance
in the latter state, owing possibly to larger individual variability
(Figure 2B). Likewise, we observed impaired glucose tolerance
that worsened progressively with age during intraperitoneal
glucose tolerance tests (Figures 2C–2F), without changes to pe-
ripheral insulin sensitivity (Figure S2). The decrease in insulin
levels implicated defective pancreatic endocrine function as
cause of hyperglycemia.
To test insulin secretory function, we subjected mice to hyper-
glycemic clamps (Delghingaro-Augusto et al., 2009). After reach-
ing steady-state hyperglycemia (Figure S2), b-Foxo KO mice
required an 50% lower rate of glucose infusion to maintain it,
owing to a commensurate decrease in insulin levels (Figures
2G–2J). These data indicate that b-Foxo KOmice have a primary
defect in glucose-dependent insulin secretion that leads to
MODY-type diabetes, i.e., early-onset, mild, and moderately
progressive (Fajans and Bell, 2011).
We therefore analyzed insulin secretion in vivo and ex vivo.
The ability of b-FoxO KOmice to respond to the ATP-dependent
K-channel blocker, glibenclamide, and to the depolarizing agent,
Figure 2. Metabolic Analyses in b-FoxO KO Mice
(A and B) Blood glucose and insulin levels in fasted, fed, and 4 hr-refed 12-week-old male mice (n = 9 WT, 10 KO mice per genotype).
(C–E) Intraperitoneal glucose tolerance tests in male mice at different ages (n = 12 WT, 8 KO mice per genotype at each age).
(F) Quantification of areas under the curve for the experiments shown in (C)–(E).
(G–I) Hyperglycemic clamps in 24-week-oldmalemice, showing glucose infusion rates (G), plasma insulin levels (I), and quantification of areas under the curve for
the experiments shown in (H) and (I) (n = 4 mice per genotype). All data are presented as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 by two-way ANOVA.
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Table 1. Summary of Pathway Analysis of Transcriptome Data
Pathway Top Genes p Value
Transcription
regulator
Hnf4a 2.0 3 1014
Hic1 1.8 3 103
Hnf1a 1.8 3 103
Nfe2L2 5.0 3 103
Pdx1 6.2 3 103
Canonical
pathways
Mitochondrial
dysfunction
5.9 3 107
Ubiquinone biosynthesis 8.0 3 106
Purine metabolism 8.8 3 105
Lysine degradation 1.5 3 104
Valine, Leucine and
Isoleucine Degradation
7.7 3 104
‘‘Toxic’’ list Mitochondrial
dysfunction
1.0 3 106
Glutathione depletion 2.9 3 102
Fatty acid metabolism 5.0 3 102
LXR/RXR activation 8.0 3 102
Oxidative stress 1.0 3 101
Biological
functions
Energy production 1.5 3 104 to 3 3 102
Molecular transport 1.5 3 104 to 3.4 3 102
Nucleic acid metabolism 1.5 3 104 to 3.4 3 102
Small molecule biochemistry 1.5 3 104 to 4.2 3 102
Cellular assembly and
organization
1.7 3 104 to 4.2 3 102
The table summarizes top pathways and transcription factors from tran-
scriptome analysis of b-FoxO KO mice.
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response of collagenase-purified islets challenged with varying
concentrations of glucose in static incubations following over-
night culture (Figure 3C). The impairment in insulin secretion
occurred in very young animals, and preceded the onset of b
cell dedifferentiation (Figure S3) (Talchai et al., 2012b). There-
fore, it is likely to foreshadow a more profound defect in b-cell
function, possibly paving the way for dedifferentiation.
Indeed, as the animals aged to 12 months, the previously
described features of b cell dedifferentiation emerged, as de-
noted by decreased expression of b cell-specific transcription
factors, Pdx1 and MafA; and increased progenitor/pluripotency
markers, Neurogenin3 (Ngn3), Nanog, Oct4, and Sox2 in
b-FoxO KO animals (Figure S1).
RNA Profiling of FoxO-Deficient Islets
To understand the molecular foundation of the observed func-
tional changes, we isolated islets from b-Foxo KO and control lit-
termates prior to the onset of hyperglycemia in b-Foxo KO and
compared transcriptomes (Tables 1, S1, S2, S3, and S4). We
used the Ingenuity pathway analysis to investigate alterations
of known pathways and molecular interactions. Interestingly,
the analysis revealed that three of the top five transcriptional net-
works affected by FoxO ablation were supervised by MODY
genes: Hnf4a (MODY 1), Hnf1a (MODJ 3), and Pdx1 (MODY4)596 Cell Metabolism 20, 593–602, October 7, 2014 ª2014 Elsevier In(Fajans and Bell, 2011) (Table 1). In addition, mitochondrial
dysfunction, including ubiquinone biosynthesis (a marker of
complex I activity), topped the list of canonical pathways and
detoxification pathways affected by FoxO ablation (Table 1).
Among listed cellular biological functions affected by triple
FoxO ablation, intracellular vesicle formation, trafficking, and
Ca2+ mobilization were predicted to have lower activities,
whereas sphingolipid cleavage, oxidation of fatty acid and lipid,
and transport of fatty acid were predicted to have higher activ-
ities (Table S1). Consistent with these predictions was also the
activation of pathways orchestrated by nuclear receptors Ppara
and Pparg (Table S2). Interestingly, most of these alterations
were also present when we analyzed transcriptomes of mice
with triple FoxO knockouts in pancreatic progenitor cells, gener-
ated using Pdx1-cre mice (J.Y.K.-M., S. Talchai, and D.A., un-
published data).
Thus, the b-FoxO KO transcriptome bears significant resem-
blance to that of b cells exposed to low glucose, including
decreased expression of genes involved in vesicle trafficking
and Ca2+ mobilization, activation of Ppara and lipid oxidation
(Joly et al., 2009; Roduit et al., 2000), suppression of protein syn-
thesis, decreased cataplerosis (Flamez et al., 2002), and
increased urea production (Webb et al., 2000). Interestingly,
low-glucose exposure is also associated with increased oxida-
tive stress, mimicking other aspects of the b-FoxO KO transcrip-
tome (Tables S1, S2, S3, and S4) (Roma et al., 2012).
Metabolic Inflexibility of b-FoxO KO Mice
These striking findings—encompassing virtually all key path-
ways required for physiologic insulin secretion—allowed us to
formulate a testable hypothesis on the physiologic role of the
three FoxO in mature b cells: the maintenance of physiologic
insulin secretion is predicated on the cell’s ability to select
substrates for mitochondrial oxidative phosphorylation among
glucose, lipids, and amino acids (Prentki and Madiraju, 2012),
a concept known as metabolic flexibility (Figure 3D) (Galgani
et al., 2008). We hypothesized that, in the absence of FoxO, b
cells lose their metabolic flexibility and increase lipid oxidation,
like starved b cells, potentially leading to mitochondrial dysfunc-
tion through peroxide formation, generation of superoxide radi-
cals, and impaired mitochondrial dynamics. This results in lower
ATP production, reduced generation, and trafficking of secretory
vesicles and decreases intracellular Ca2+ signaling, impairing in-
sulin secretion (Figure 3E).
To test the metabolic flexibility of FoxO-deficient b cells, we
performed batch incubations of purified islets to measure
glucose and lipid metabolism. Consistent with in vivo data
and transcriptome analyses, we found that glucose oxidation
to CO2 was impaired by 50% at every glucose concentration
tested, except 2.8 mM (Figure 4A). Glucose utilization was pre-
served, indicating that there is a specific defect in mitochondrial
glucose metabolism (Figure 4B) (Joly et al., 2009). Conversely,
palmitate oxidation by b-FoxO KO islets in the presence of
basal glucose was 2-fold higher, and nearly 2.5-fold higher
when incubations were performed in high glucose (Figure 4C).
Glycerolipid synthesis of FoxO-deficient islets, in contrast,
was comparable to that of control islets at low glucose concen-
trations, but failed to increase at elevated glucose concentra-
tions, resulting in lower conversion of labeled palmitate intoc.
Figure 3. Insulin Secretion and Working
Model
(A and B) Glibenclamide- and l-arginine-induced
insulin secretion in vivo (n = 8 mice per group).
(C) Glucose-induced insulin release from collage-
nase-purified islets stimulated with glucose or KCl
(n = 3 per group). Each experiment was performed
with pooled islets from three to four mice per ge-
notype. Each data point consists of four replicates.
All data are presented as means ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.001 by two-way ANOVA (A and
B) or one-factor ANOVA (C).
(D and E) Model of FoxO regulation of insulin
secretion in pathophysiologic conditions. FoxO
nuclear translocation mediates the effects of
glucose on gene expression through MODY gene
networks (Buteau et al., 2007; Kitamura et al.,
2005), allowing glucose flux into mitochondria
(thick arrows), with smaller contributions by lipids
and amino acids (thin dotted arrows). (E) As FoxOs
become functionally exhausted, b cells are tran-
scriptionally blindsided to the effects of glucose,
increasing lipid and amino acid flux. MODY genes
are suppressed, and Ppar’s are increased,
consistent with the role of FoxO to suppress Ppara
in liver (Matsumoto et al., 2006) and Pparg in fat
(Nakae et al., 2003). PC, pyruvate carboxylase;
GDH, glutamate dehydrogenase; Cpt1, carnitine
palmitoyltransferase-1.
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contrast, monoacylglyceride formation was unaffected (Fig-
ure 4F), as was phospholipid and FFA synthesis (Figure S4).
These data show that FoxO-deficient b cells are impaired in
their ability to switch from lipid to glucose oxidation as glucose
concentrations rise. Moreover, they show that, unlike normal b
cells—which redirect acyl groups from lipid oxidation to triglyc-
eride synthesis as glucose levels increase—FoxO-deficient b
cells appear to be locked in a lipid oxidative state. Consistent
with this idea, we observed that the impairment of glucose-
induced insulin release in b-FoxO KO islets could be partly
reversed by adding the fatty acid oxidation inhibitor etomoxir
to the culture medium. In contrast, pyruvate-induced insulin
secretion was similar in islets of both genotypes (Figure S4)
(Sener et al., 1978).
If metabolic inflexibility had adverse consequences on b cell
function, it should affect mitochondrial ATP generation. Hence,Cell Metabolism 20, 593–60we tested mitochondrial function in puri-
fied islets. Basal cellular respiration (oxy-
gen consumption rates, OCR), ATP turn-
over (oligomycin-sensitive respiration),
proton leak (oligomycin-insensitive respi-
ration), and maximal respiration (FCCP-
induced) were identical between control
and knockout animals. Raising glucose
concentrations from 3 to 20 mM more
than doubled ATP turnover in control is-
lets but had hardly any effect in KO islets.
Addition of the electron transport chain in-
hibitor rotenone suppressed OCR in both
groups to the same extent, indicating thatnonmitochondrial respiration was unaffected (Figure 5A). As a
result of the decreased glucose-induced oxygen consumption,
the glucose-dependent OCR area under the curve was reduced
by 35% in b-FoxO KO islets (Figure 5B). The selective impair-
ment of glucose-dependent OCR is consistent with RNA
profiling data of lower complex I function.
Insulin secretion is induced by rising ATP/ADP ratios (Mat-
schinsky, 1996). The ADP-stimulated rate, calculated as the dif-
ference between coupled OCR and basal OCR, was >60% lower
in b-FoxO KO islets (Figure 5C). Finally, glucose-induced ATP
generation was also blunted in b-FoxO KO (Figure 5D). These
changes were not related to changes in mitochondria size and
density as assessed by electron microscopy (data not shown).
The mitochondrial analysis thus supports the hypothesis of
impaired metabolic flexibility.
Ca2+ mobilization is required for proper intracellular assem-
bly and mobilization of secretory vesicles, leading to insulin2, October 7, 2014 ª2014 Elsevier Inc. 597
Figure 4. Glucose and Lipid Metabolism in
Isolated Islets
(A) 3H-glucose oxidation.
(B) 14C-glucose utilization.
(C) Palmitate oxidation.
(D–F) diacylglycerol (D), triglyceride (E), and mon-
oacylglycerol synthesis (F) from 14C-labeled
palmitate (n = 3 per group). Each experiment was
performed with pooled islets from five mice per
genotype. Each data point consists of six to nine
replicates. Glc, glucose; Pal, palmitate. All data are
presented as means ± SEM. *p < 0.05, **p < 0.01,
***p < 0.001 by Student’s t test.
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Triple FoxO Knockout in Pancreatic b Cellsexocytosis (Rorsman et al., 2012). mRNA profiling data were
consistent with impaired activation of networks required for
Ca2+ mobilization, signaling, and vesicle transport in b-FoxO
KO mice (Table S1). Accordingly, we found that membrane de-
polarization-induced Ca2+ influx in response to rising glucose
concentrations was considerably lower in b cells lacking FoxO
(Figure 6A). b-FoxO KO islets showed lower levels of mRNAs
encoding a subunits of L-type voltage-gated Ca2+channels,
Ca2+-dependent as well as Ca2+-independent (but PMA-sensi-
tive) protein kinase C, inositol-phosphate receptors 1–3, and
several phospholipase C isoforms (Figure 6B). We also validated
RNA profiling data by measuring expression of a subset of target
genes in calcium metabolism (Figure S5). To provide functional
evidence for these changes, we examined insulin secretion
from purified islets in response to a variety of Ca2+-dependent
secretagogues. We found lower insulin secretion in response
to the sulfonylurea glibenclamide, the PKC activator PMA, and
the L-type Ca channel activator Bay-K8644. In contrast, re-
sponses to the cAMP-agonists IBMX and forskolin were pre-
served (Figure 6C).598 Cell Metabolism 20, 593–602, October 7, 2014 ª2014 Elsevier Inc.DISCUSSION
The key finding of this work is that a com-
plete loss of FoxO function that includes
FoxO1, FoxO3a, and FoxO4—as might
be expected in multiple forms of b cell
dysfunction (Talchai et al., 2012b)—
causes MODY-like diabetes through
reduced metabolic flexibility of b cells.
Our interpretation is that FoxOs are
collectively required to maintain MODY-
related gene networks, which in turn are
required to enable a gene expression
program that permits proper substrate
selection (glucose versus fatty acids) for
mitochondrial oxidative phosphorylation.
We suggest that metabolic inflexibility
caused by progressive loss of FoxO (Tal-
chai et al., 2012b) is the mechanism un-
derlying the progression from impaired
insulin secretion to dedifferentiation,
leading to a loss of b cell mass.
FoxOs are activated by hyperglyce-
mia-induced oxidative stress in b cells
(Kawamori et al., 2006; Kitamura et al.,2005). Under appropriate experimental conditions, there is a
transient effect of glucose to promote FoxO nuclear exclusion,
arguably in response to autocrine insulin signaling (Martinez
et al., 2006). But this may reflect a specific situation made
possible by the lower insulin content and more extreme
glucose deprivation in vitro, rather than a physiologic mecha-
nisms, as we have suggested (Kitamura et al., 2005). We
have proposed that, as they rapidly respond to the b cell’s
nutritional state, FoxOs are better positioned to translate the
latter into an appropriate transcriptional program than other
transcription factors that don’t respond as nimbly to changes
in glucose, lipid, and hormone levels (Talchai et al., 2009). If
the stress persists, FoxO levels drop through deacetylation-
induced degradation that prevents the normal autoregulatory
loop of FoxO expression (Kitamura et al., 2005; Talchai et al.,
2012a). We now report that the loss of all three FoxOs (likely
through similar mechanisms) impairs the homeostatic MODY-
related gene network and activates Ppara-dependent lipid
oxidative pathways, possibly resulting in increased supply of
fatty acyl-derived acetyl-CoA for mitochondrial oxidation. That
Figure 5. Mitochondrial Function in Isolated
Islets
(A and B) Time course and area under the curve
(AUC) of oxygen consumption rates measured in
collagenase-purified islets from wild-type and
b-FoxO KO mice. Oligomycin inhibits ATP syn-
thase, FCCP is an uncoupler, and rotenone is an
inhibitor of complex I (n = 3 per group). Each
experiment was performed with pooled islets from
fivemice per genotype. Each data point consists of
ten replicates.
(C) ADP-stimulated rate of ATP generation, calcu-
lated as the difference between coupled and
basal OCR.
(D) ATP content of pancreatic islets of wild-type
and b-FoxO mice quantified at different glucose
concentrations (n = 3 per group). Each experiment
was performed with pooled islets from three mice
per genotype. Each data point consists of five
replicates. All data are presented asmeans ± SEM.
*p < 0.05, **p < 0.01 by Student’s t test.
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and TG synthesis despite the predicted activation of the Pparg
network suggests that the latter event has a compensatory
character, possibly aimed at preventing excessive lipid oxida-
tion. This finding provides a potential explanation for the clinical
benefits of Pparg agonists on b cell function, i.e., that they
shunt lipids from oxidation to synthesis, preventing lipid-fueled
toxicity (Defronzo et al., 2013; Leahy, 2009). Enhanced fatty
acid oxidation and reduced lipid esterification processes will
also result in altered glycerolipid/fatty acid cycling and produc-
tion of lipid mediators for glucose-induced insulin secretion
(Prentki et al., 2013). Thus, FoxOs appear to control both mito-
chondrial (e.g., ATP) and lipid signals for glucose-stimulated in-
sulin release.
How do FoxOs oversee such a vast functional b cell network?
A potential explanation is that FoxOs are required to enforce the
HNF4a network, and that the others are dependent on HNF4a
(Gupta et al., 2005; Odom et al., 2004). Alternatively, FoxO could
be orchestrating higher-level changes in genome maintenance,
for example through Hic1, a transcriptional repressor with a po-
tential role in genome methylation (Pinte et al., 2004) that figures
prominently among FoxO transcriptome changes, and regulates
two important networks in b cell function, Tcf7L2 and EphA2
(Foveau et al., 2012; Valenta et al., 2006).
When viewed in the context of prior data indicating a role of
FoxO in the acute response to hyperglycemia-induced oxida-
tive stress (Kawamori et al., 2006; Kitamura et al., 2005), and
the chronic role of FoxO1 in b cell lineage maintenance and dif-
ferentiation (Talchai et al., 2012b), the data begin to outline a
unified theory that bridges the two cornerstones of diabetic b
cell failure: reduced function and impaired mass (Accili et al.,
2010). Not only that, but the data provide a heretofore missing
link between metabolic alterations and regulation of MODY1,Cell Metabolism 20, 593–60MODY3, and MODY4 genes that serves
as a paradigm for the connection be-
tween genetic and acquired b cell
abnormalities. The transcriptome of
FoxO-deficient b cells provides a richmenu to design better therapies to combat b cell dysfunction
in type 2 diabetes.
EXPERIMENTAL PROCEDURES
Animals
We performed genotyping as described (Kitamura et al., 2009; Tsuchiya et al.,
2012). Mice were maintained on a mixed 129J-C57BL/6 background. As con-
trols, owing to the complexity of genotyping the six mutant alleles (five Foxo
alleles and Rip-cre), we used different combinations of FoxO1, FoxO3, and
FoxO4 floxed mice without Rip-cre transgene or Rip-cre mice without FoxO
floxed alleles (Xuan et al., 2002). These mice were indistinguishable from
mixed 129J-C57BL/6 mice in all metabolic tests. All mice were fed normal
chow and maintained on a 12 hr light-dark cycle (lights on at 7 a.m.). All exper-
iments were performed in 12- to 20-week-old male mice, unless specified
otherwise in figure legends. The Columbia University Institutional Animal
Care and Utilization Committee approved all experiments.
RNA Profiling
We used GeneChip Mouse Exon arrays (Affymetrix) and performed data anal-
ysis with Partek Genomics Suite (Partek, Inc.) and Ingenuity Pathway Analysis
(Ingenuity System, Inc.). For the analyses shown in this study, we used a
threshold of p < 0.05 and >1.3-fold change (n = 4 WT, 3 KO per group; each
array was performed with pooled islets from three mice per genotype).
Metabolic Analyses
Weperformedglucose tolerance tests inovernight-fastedmiceby intraperitoneal
injection of glucose (2 g/kg) (Xuanet al., 2010).WeperformedGSISand arginine-
induced insulin secretion tests as described (Kido et al., 2000). We measured
glucagon by radioimmunoassay and insulin by ELISA (Millipore). We performed
hyperglycemic glucose clamps as described (Delghingaro-Augusto et al., 2009).
Immunoblot, Immunohistochemistry, and Morphometry
Western blots used the primary antibodies directed against the following pro-
teins: Foxo1, Foxo3, Foxo4, and a-tubulin from Cell Signaling (#2880, 2497,
9472, and 2144). We fixed and processed tissues for immunohistochemistry
as described (Kitamura et al., 2009). We applied perfused fixation and antigen2, October 7, 2014 ª2014 Elsevier Inc. 599
Figure 6. Ca2+ Flux in Isolated Islets
(A) Ca2+influx measured by Fura2 AM loading in
isolated islets incubated with the indicated
amounts of glucose (n = 3 per group). Each
experiment was performed with pooled islets
from two mice per genotype. Each data point
consists of four replicates. All data are presented
as means ± SEM. *p < 0.05 by one-factor
ANOVA.
(B) mRNA levels of genes involved in Ca homeo-
stasis, Cacna, a subunits isoforms of L-type
voltage-gated Ca2+ channels; Itpr, in-
ositolphosphate receptor; Pkc, Ca2+-sensitive and
-insensitive protein kinase C; Plc, phospholipase
C. Data are expressed as percent of wild-type
values and were obtained in pancreatic islets of
10-week-old control and b-FoxO mice (n = 9–12
per genotype).
(C) Secretagogue-stimulated insulin secretion in
isolated islets incubated with glucose (2.8 mM
and 11.2 mM), glibenclamide (1 mM), PMA (1 mM),
Bay K-8644 (0.5 mM), forskolin (5 mM), and IBMX
(0.5 mM) in the presence of 11.2 mM glucose (n =
3 per group). Each experiment was performed
with pooled islets from five mice per genotype.
Each data point consists of four replicates. PMA,
Phorbol myristate acetate; IBMX, 3-isobutyl-1-
methylxanthine. All data are presented as
means ± SEM. *p < 0.05, **p < 0.01 by Student’s
t test.
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2012b). We used anti-Foxo1 (Cell Signaling #2880), anti-insulin, and anti-
glucagon from Dako (#A056401-2, A056501-2) for primary antibodies and
FITC-, Cy3-, and Alexa-conjugated donkey secondary antibodies (Jackson
Immunoresearch Laboratories, and Molecular Probes) (Kitamura et al.,
2009). Antibodies to Pcsk1, Pcsk2, Glut-2, and Pdx-1 were from EMDMillipore
(#AB10553, AB15610, 07-1402, 061384). For b cell morphometry, four pancre-
atic sections from four mice from each genotype were sampled 150 mm apart
and used for a two-tailed paired Student’s t test analysis. Total pancreas area
was captured at 1003 and immunostaining area at 2003 (Talchai et al.,
2012b). The ratio of immunoreactive area/pancreas area was converted
from pixel to mm2 and plotted as mm2.
Mitochondrial Function
We used the XF24-3 respirometer (Seahorse Bioscience) with 24-well plates
designed to confine islets. We used the F1F0 ATP synthase inhibitor oligomycin
to assess uncoupling, FCCP to estimate maximum respiration, and rotenone
to measure nonmitochondrial respiration (Qiang et al., 2012).
Ca2+ Influx
We isolated pancreatic islets by collagenase digestion and resuspended them
in RPMI. Fura-2 fluorescence was recorded (Delta Ram; PTI Inc., South Bruns-600 Cell Metabolism 20, 593–602, October 7, 2014 ª2014 Elsevier Inc.wick, NJ) in an RC-20 bath flow chamber (Warner
Instrument Corp., Hamden, CT) at excitation wave-
lengths of 340 and 380 nm (Srivastava et al., 2012).
Data are represented as 340/380 ratios after back-
ground subtraction.
Glucose and Lipid Metabolism
After overnight recovery and 2 hr starvation, 20
islets were preincubated in KRBH for 45 min at
2.8 mM glucose followed by incubation in KRBH
containing 0.5 mCi of [5-3H] D-glucose (16 Ci/
mmol) and 1 mCi/ml [U-14C] D-glucose (250 mCi/
mmol) at 2.8, 8.3, and 16.7 mM glucose. Incuba-tion was terminated by the addition of citrate/NaOH buffer (400 mM, pH 4.9)
containing antimycin-A (10 M), rotenone (10 M), and KCN (5 mM). Glucose
oxidation was measured by the generation of KO-trapped 14CO2 after
60 min (Buteau et al., 2007). Glucose utilization was determined by
measuring 3H2O (Buteau et al., 2007). Lipid oxidation and triglyceride synthe-
sis from glycerol were measured as described (Delghingaro-Augusto et al.,
2009). Islets were cultured in RPMI with 5.5 mM glucose, 0.25% (w/v) defat-
ted BSA, 0.1 mM palmitate, and [9,10(n)-3H]-palmitate (74 kBq/ml) for 16 hr
at 37C. They were washed in KRBH supplemented with 0.25% (w/v) BSA,
3 mM glucose, and 0.1 mM palmitate, followed by 2 hr incubation in
KRBH supplemented with 0.25% (w/v) BSA, 0.1 mM palmitate,
[9,10(n)-3H]-palmitate (74 kBq/ml), 1 mM carnitine, and 3, 8, or 16 mM
glucose. The supernatant was collected and frozen to separate 3H2O from
labeled fatty acids prior to counting 3H2O radioactivity. For fatty acid ester-
ification, islets were cultured for 16 hr at 37C in RPMI with 3 or 16 mM
glucose, 0.25% (w/v) defatted BSA, 0.1 mM palmitate, and [1-14C]-palmitate
(37 kBq/ml). They were collected, washed, and resuspended in Folch
reagent. Total lipids were extracted and separated by thin-layer chroma-
tography using petroleum ether/ethyl-ether/acetic acid (70:30:1). Spots
corresponding to phospholipids, monoacylglycerol, diacylglycerol, and tria-
cylglycerol were visualized by autoradiography and counted (Delghingaro-
Augusto et al., 2009).
Cell Metabolism
Triple FoxO Knockout in Pancreatic b CellsRNA Measurements
We used standard techniques for mRNA isolation and quantitative PCR. PCR
primer sequences have been published (Talchai et al., 2012b). Data have been
deposited as GEO GSE60505.
Statistical Analyses and General Methods
Sample sizes were estimated from expected effect size based on previous ex-
periments. No randomization or blinding was used. We present data as
means ± SEM. We used two-tailed Student’s t test, one-way ANOVA, or
two-way ANOVA for data analysis and the customary threshold of p < 0.05
to declare statistically significant differences.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and four tables and can be
found with this article at http://dx.doi.org/10.1016/j.cmet.2014.08.012.
ACKNOWLEDGMENTS
This work was supported by grants from NIH DK64819, DK63608 (Columbia
University Diabetes Research Center), DK20541 (Einstein College of Medicine
Diabetes Research Center), Brehm Coalition, JPB Foundation, Canadian Insti-
tute of Health Research, Diabe`te Que´bec, Montreal Diabetes Research Cen-
ter, and Fonds de Recherche du Que´bec Sante´. M.P. holds the Canada Chair
in Diabetes and Metabolism. We are grateful to members of the Accili labora-
tory for insightful data discussions. We thank Mr. Thomas Kolar and Ms. Ana
Flete-Castro (Columbia University) for outstanding technical support.
Received: March 7, 2014
Revised: June 25, 2014
Accepted: August 22, 2014
Published: September 25, 2014
REFERENCES
Accili, D., Ahre´n, B., Boitard, C., Cerasi, E., Henquin, J.C., and Seino, S. (2010).
What ails the b-cell? Diabetes Obes. Metab. 12 (Suppl 2 ), 1–3.
Buteau, J., Shlien, A., Foisy, S., and Accili, D. (2007). Metabolic diapause in
pancreatic beta-cells expressing a gain-of-function mutant of the forkhead
protein Foxo1. J. Biol. Chem. 282, 287–293.
Defronzo, R.A., Tripathy, D., Schwenke, D.C., Banerji, M., Bray, G.A.,
Buchanan, T.A., Clement, S.C., Gastaldelli, A., Henry, R.R., Kitabchi, A.E.,
et al. (2013). Prevention of diabetes with pioglitazone in act now: physiologic
correlates. Diabetes 62, 3920–3926.
Delghingaro-Augusto, V., Nolan, C.J., Gupta, D., Jetton, T.L., Latour, M.G.,
Peshavaria, M., Madiraju, S.R., Joly, E., Peyot, M.L., Prentki, M., and Leahy,
J. (2009). Islet beta cell failure in the 60% pancreatectomised obese
hyperlipidaemic Zucker fatty rat: severe dysfunction with altered glycerolipid
metabolism without steatosis or a falling beta cell mass. Diabetologia 52,
1122–1132.
Fajans, S.S., and Bell, G.I. (2011). MODY: history, genetics, pathophysiology,
and clinical decision making. Diabetes Care 34, 1878–1884.
Ferrannini, E. (2010). The stunned b cell: a brief history. Cell Metab. 11,
349–352.
Flamez, D., Berger, V., Kruhøffer, M., Orntoft, T., Pipeleers, D., and Schuit, F.C.
(2002). Critical role for cataplerosis via citrate in glucose-regulated insulin
release. Diabetes 51, 2018–2024.
Foveau, B., Boulay, G., Pinte, S., Van Rechem, C., Rood, B.R., and Leprince,
D. (2012). The receptor tyrosine kinase EphA2 is a direct target gene of hyper-
methylated in cancer 1 (HIC1). J. Biol. Chem. 287, 5366–5378.
Galgani, J.E., Moro, C., and Ravussin, E. (2008). Metabolic flexibility and insu-
lin resistance. Am. J. Physiol. Endocrinol. Metab. 295, E1009–E1017.
Gupta, R.K., Vatamaniuk, M.Z., Lee, C.S., Flaschen, R.C., Fulmer, J.T.,
Matschinsky, F.M., Duncan, S.A., and Kaestner, K.H. (2005). The MODY1
gene HNF-4alpha regulates selected genes involved in insulin secretion.
J. Clin. Invest. 115, 1006–1015.CellJoly, E., Roduit, R., Peyot, M.L., Habinowski, S.A., Ruderman, N.B., Witters,
L.A., and Prentki, M. (2009). Glucose represses PPARalpha gene expression
via AMP-activated protein kinase but not via p38 mitogen-activated protein
kinase in the pancreatic beta-cell. J. Diabetes 1, 263–272.
Kawamori, D., Kaneto, H., Nakatani, Y., Matsuoka, T.A., Matsuhisa, M., Hori,
M., and Yamasaki, Y. (2006). The forkhead transcription factor Foxo1 bridges
the JNK pathway and the transcription factor PDX-1 through its intracellular
translocation. J. Biol. Chem. 281, 1091–1098.
Kido, Y., Burks, D.J., Withers, D., Bruning, J.C., Kahn, C.R., White, M.F., and
Accili, D. (2000). Tissue-specific insulin resistance inmicewith mutations in the
insulin receptor, IRS-1, and IRS-2. J. Clin. Invest. 105, 199–205.
Kitamura, T., Nakae, J., Kitamura, Y., Kido, Y., Biggs, W.H., 3rd, Wright, C.V.,
White, M.F., Arden, K.C., and Accili, D. (2002). The forkhead transcription fac-
tor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell
growth. J. Clin. Invest. 110, 1839–1847.
Kitamura, Y.I., Kitamura, T., Kruse, J.P., Raum, J.C., Stein, R., Gu, W., and
Accili, D. (2005). FoxO1 protects against pancreatic beta cell failure through
NeuroD and MafA induction. Cell Metab. 2, 153–163.
Kitamura, T., Kitamura, Y.I., Kobayashi, M., Kikuchi, O., Sasaki, T., Depinho,
R.A., and Accili, D. (2009). Regulation of pancreatic juxtaductal endocrine
cell formation by FoxO1. Mol. Cell. Biol. 29, 4417–4430.
Leahy, J.L. (2009). Thiazolidinediones in prediabetes and early type 2 diabetes:
what can be learned about that disease’s pathogenesis. Curr. Diab. Rep. 9,
215–220.
Martinez, S.C., Cras-Me´neur, C., Bernal-Mizrachi, E., and Permutt, M.A.
(2006). Glucose regulates Foxo1 through insulin receptor signaling in the
pancreatic islet beta-cell. Diabetes 55, 1581–1591.
Matschinsky, F.M. (1996). Banting Lecture 1995. A lesson in metabolic regula-
tion inspired by the glucokinase glucose sensor paradigm. Diabetes 45,
223–241.
Matsumoto, M., Han, S., Kitamura, T., and Accili, D. (2006). Dual role of tran-
scription factor FoxO1 in controlling hepatic insulin sensitivity and lipid meta-
bolism. J. Clin. Invest. 116, 2464–2472.
Nakae, J., Kitamura, T., Kitamura, Y., Biggs, W.H., 3rd, Arden, K.C., and Accili,
D. (2003). The forkhead transcription factor Foxo1 regulates adipocyte differ-
entiation. Dev. Cell 4, 119–129.
National Institute of Diabetes and Digestive and Kidney Diseases (2005).
National Diabetes Statistics fact sheet: general information and national esti-
mates on diabetes in the United States. (Bethesda, MD: U.S. Department of
Health and Human Services, National Institute of Health).
Odom, D.T., Zizlsperger, N., Gordon, D.B., Bell, G.W., Rinaldi, N.J., Murray,
H.L., Volkert, T.L., Schreiber, J., Rolfe, P.A., Gifford, D.K., et al. (2004).
Control of pancreas and liver gene expression by HNF transcription factors.
Science 303, 1378–1381.
Paik, J.H., Kollipara, R., Chu, G., Ji, H., Xiao, Y., Ding, Z., Miao, L., Tothova, Z.,
Horner, J.W., Carrasco, D.R., et al. (2007). FoxOs are lineage-restricted redun-
dant tumor suppressors and regulate endothelial cell homeostasis. Cell 128,
309–323.
Pinte, S., Stankovic-Valentin, N., Deltour, S., Rood, B.R., Gue´rardel, C., and
Leprince, D. (2004). The tumor suppressor gene HIC1 (hypermethylated in
cancer 1) is a sequence-specific transcriptional repressor: definition of its
consensus binding sequence and analysis of its DNA binding and repressive
properties. J. Biol. Chem. 279, 38313–38324.
Prentki, M., and Madiraju, S.R. (2012). Glycerolipid/free fatty acid cycle and
islet b-cell function in health, obesity and diabetes. Mol. Cell. Endocrinol.
353, 88–100.
Prentki, M., Matschinsky, F.M., and Madiraju, S.R. (2013). Metabolic signaling
in fuel-induced insulin secretion. Cell Metab. 18, 162–185.
Qiang, L., Wang, L., Kon, N., Zhao, W., Lee, S., Zhang, Y., Rosenbaum, M.,
Zhao, Y., Gu, W., Farmer, S.R., and Accili, D. (2012). Brown remodeling of
white adipose tissue by SirT1-dependent deacetylation of Pparg. Cell 150,
620–632.Metabolism 20, 593–602, October 7, 2014 ª2014 Elsevier Inc. 601
Cell Metabolism
Triple FoxO Knockout in Pancreatic b CellsRahier, J., Guiot, Y., Goebbels, R.M., Sempoux, C., and Henquin, J.C. (2008).
Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes
Obes. Metab. 10 (Suppl 4 ), 32–42.
Reaven, G.M. (1995). Pathophysiology of insulin resistance in human disease.
Physiol. Rev. 75, 473–486.
Roduit, R., Morin, J., Masse´, F., Segall, L., Roche, E., Newgard, C.B.,
Assimacopoulos-Jeannet, F., and Prentki, M. (2000). Glucose down-regulates
the expression of the peroxisome proliferator-activated receptor-alpha gene in
the pancreatic beta -cell. J. Biol. Chem. 275, 35799–35806.
Roma, L.P., Pascal, S.M., Duprez, J., and Jonas, J.C. (2012). Mitochondrial
oxidative stress contributes differently to rat pancreatic islet cell apoptosis
and insulin secretory defects after prolonged culture in a low non-stimulating
glucose concentration. Diabetologia 55, 2226–2237.
Rorsman, P., Braun, M., and Zhang, Q. (2012). Regulation of calcium in
pancreatic a- and b-cells in health and disease. Cell Calcium 51, 300–308.
Savage, P.J., Bennion, L.J., Flock, E.V., Nagulesparan, M., Mott, D., Roth, J.,
Unger, R.H., and Bennett, P.H. (1979). Diet-induced improvement of abnor-
malities in insulin and glucagon secretion and in insulin receptor binding in dia-
betes mellitus. J. Clin. Endocrinol. Metab. 48, 999–1007.
Sener, A., Kawazu, S., Hutton, J.C., Boschero, A.C., Devis, G., Somers, G.,
Herchuelz, A., and Malaisse, W.J. (1978). The stimulus-secretion coupling of
glucose-induced insulin release. Effect of exogenous pyruvate on islet func-
tion. Biochem. J. 176, 217–232.
Srivastava, S., Cai, X., Li, Z., Sun, Y., and Skolnik, E.Y. (2012).
Phosphatidylinositol-3-kinase C2b and TRIM27 function to positively and
negatively regulate IgE receptor activation of mast cells. Mol. Cell. Biol. 32,
3132–3139.
Talchai, C., Lin, H.V., Kitamura, T., and Accili, D. (2009). Genetic and biochem-
ical pathways of beta-cell failure in type 2 diabetes. Diabetes Obes. Metab. 11
(Suppl 4 ), 38–45.602 Cell Metabolism 20, 593–602, October 7, 2014 ª2014 Elsevier InTalchai, C., Xuan, S., Kitamura, T., DePinho, R.A., and Accili, D. (2012a).
Generation of functional insulin-producing cells in the gut by Foxo1 ablation.
Nat. Genet. 44, 406–412, S1.
Talchai, C., Xuan, S., Lin, H.V., Sussel, L., and Accili, D. (2012b). Pancreatic b
cell dedifferentiation as a mechanism of diabetic b cell failure. Cell 150, 1223–
1234.
Tsuchiya, K., Tanaka, J., Shuiqing, Y., Welch, C.L., DePinho, R.A., Tabas, I.,
Tall, A.R., Goldberg, I.J., and Accili, D. (2012). FoxOs integrate pleiotropic ac-
tions of insulin in vascular endothelium to protect mice from atherosclerosis.
Cell Metab. 15, 372–381.
Valenta, T., Lukas, J., Doubravska, L., Fafilek, B., and Korinek, V. (2006). HIC1
attenuates Wnt signaling by recruitment of TCF-4 and beta-catenin to the nu-
clear bodies. EMBO J. 25, 2326–2337.
Webb, G.C., Akbar, M.S., Zhao, C., and Steiner, D.F. (2000). Expression
profiling of pancreatic beta cells: glucose regulation of secretory and meta-
bolic pathway genes. Proc. Natl. Acad. Sci. USA 97, 5773–5778.
Weyer, C., Bogardus, C., Mott, D.M., and Pratley, R.E. (1999). The natural his-
tory of insulin secretory dysfunction and insulin resistance in the pathogenesis
of type 2 diabetes mellitus. J. Clin. Invest. 104, 787–794.
Xuan, S., Kitamura, T., Nakae, J., Politi, K., Kido, Y., Fisher, P.E., Morroni, M.,
Cinti, S., White, M.F., Herrera, P.L., et al. (2002). Defective insulin secretion in
pancreatic beta cells lacking type 1 IGF receptor. J. Clin. Invest. 110, 1011–
1019.
Xuan, S., Szabolcs, M., Cinti, F., Perincheri, S., Accili, D., and Efstratiadis, A.
(2010). Genetic analysis of type-1 insulin-like growth factor receptor signaling
through insulin receptor substrate-1 and -2 in pancreatic beta cells. J. Biol.
Chem. 285, 41044–41050.c.
